Hermetica Superfood Encyclopedia
The Short Answer
Iron Sucrosomial delivers ferric pyrophosphate encased in a phospholipid-sucrester (sucrosome) matrix that resists gastric acid dissolution and enables transcellular and paracellular uptake via intestinal enterocytes and M cells, bypassing the conventional DMT-1 ferrous absorption pathway. In a clinical trial of 25 Hodgkin's Lymphoma patients receiving 30 mg elemental iron daily for six months, hemoglobin rose from 10.2 to 12.8 g/dL (+2.6 g/dL, p<0.05) with 100% compliance and zero gastrointestinal adverse events, illustrating absorption efficacy clinically comparable to intravenous iron.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordiron sucrosomial benefits
Iron Sucrosomial — botanical close-up
Health Benefits
**Iron Deficiency Anemia (IDA) Correction**
Ferric pyrophosphate within the sucrosome matrix is absorbed 3–4× more efficiently than ferrous sulfate, enabling rapid restoration of hemoglobin, serum ferritin, and serum iron levels even in patients with underlying inflammation or malabsorption.
**Superior Gastrointestinal Tolerability**
The sucrosome matrix prevents premature iron release in the stomach, reducing GI adverse events (nausea, bloating, constipation) to fewer than 5% of users compared with up to 70% for conventional ferrous salts, dramatically improving patient adherence.
**Efficacy in Oncology-Related Anemia**
Clinical data in Hodgkin's Lymphoma patients demonstrated a +2.6 g/dL hemoglobin increase over six months at 30 mg/day, alongside a ferritin rise from 90 to 277 ng/mL, supporting use during or after chemotherapy where IV iron is burdensome.
**Heart Failure and Iron Deficiency Management**
Preliminary evidence in patients with heart failure with reduced ejection fraction (HFrEF) and concurrent iron deficiency shows improvements in exercise capacity and quality-of-life scores, suggesting utility in cardiological settings where GI tolerance is critical.
**Alternative to Intravenous Iron**
Across more than 150 studies involving over 7,000 participants, Sucrosomial® Iron produced hematological responses comparable to IV iron formulations, positioning it as a first-line oral option for patients who are refractory to or intolerant of standard oral iron salts.
**Absorption Independent of Dietary and Drug Interference**
Because sucrosomal iron bypasses hepcidin-regulated DMT-1 pathways and gastric acid dissolution, its uptake is minimally affected by co-ingestion of proton pump inhibitors, antacids, calcium, or tannins that typically impair ferrous salt absorption.
**Pediatric and Special-Population Suitability**
The low adverse-effect burden and once-daily 30 mg dosing make Sucrosomial® Iron applicable in pediatric patients, pregnant women, dialysis patients, and the elderly, populations in whom conventional iron salts are frequently discontinued due to intolerance.
Origin & History
Natural habitat
Iron Sucrosomial is not a naturally occurring mineral form but a patented pharmaceutical-grade formulation developed by PharmaNutra S.p.A. (Italy) over more than two decades of research, culminating in 14 granted patents. The active iron component, ferric pyrophosphate (Fe³⁺), is encapsulated within a sucrosome matrix composed of food-grade phospholipids (lecithin) and sucrester (sucrose esters of fatty acids), creating a stable nanoparticle vehicle. This technology was first validated in preclinical models around 2016 and is now distributed in over 90 countries under brand names such as Sideral® Forte.
“Iron Sucrosomial has no history in traditional or herbal medicine systems; it is entirely a product of modern pharmaceutical innovation developed in the early 21st century by PharmaNutra S.p.A., a Pisan biotechnology company specializing in mineral delivery technologies. The concept of lipid-based encapsulation for oral drug delivery emerged in the 1980s–1990s with liposomal drug research, but the specific sucrosome platform—combining lecithin phospholipids with sucrester (sucrose esters of fatty acids) to achieve gastric resistance without enteric coating—represents a distinct technological advance first described in patent literature in the 2000s. Preclinical mechanistic validation using ex vivo intestinal models was published around 2016, after which clinical adoption accelerated rapidly, with the product registered in over 90 countries by the early 2020s. The formulation's development was driven by a well-recognized clinical unmet need: the majority of patients prescribed conventional ferrous iron salts discontinue therapy within weeks due to GI intolerance, creating a documented gap between prescribed and effective iron repletion globally.”Traditional Medicine
Scientific Research
The clinical evidence base for Sucrosomial® Iron is substantial for an oral iron formulation, encompassing more than 150 published studies with over 7,000 participants across diverse indications including iron deficiency anemia, oncology, heart failure, pediatrics, dialysis, and inflammatory bowel disease, although a significant proportion are open-label or observational in design rather than double-blind placebo-controlled RCTs. A key interventional trial in 25 Hodgkin's Lymphoma patients (median age 35, stage ≥2B) documented statistically significant improvements in hemoglobin (+2.6 g/dL), serum iron (+60 µg/dL), and ferritin (+187 ng/mL) over six months of 30 mg/day dosing with p<0.05 significance, zero GI side effects, and 100% treatment compliance. Comparative bioavailability studies demonstrate 3–4× greater absorption versus ferrous sulfate and 2.5× versus ferric bisglycinate, with pharmacokinetic profiles approaching those of intravenous iron sucrose in head-to-head trials, though these comparisons are based largely on surrogate hematological endpoints rather than long-term hard clinical outcomes. The overall evidence tier is moderate-to-strong for short-term hematological efficacy and tolerability, but larger, multicenter, double-blind RCTs with long-term cardiovascular or mortality endpoints are still needed to fully establish equivalence with IV iron in high-acuity settings.
Preparation & Dosage
Traditional preparation
**Standard Oral Capsule (Sideral® Forte)**
30 mg elemental iron per capsule once daily; this is the most widely studied dose across adult IDA, oncology, and chronic disease trials
**Pediatric Formulations**
15–30 mg elemental iron daily are available in some markets; dosing is weight-adjusted per clinical guidelines
Sachet and liquid preparations providing .
**Standardization**
30 mg Fe as ferric pyrophosphate) within a fixed phospholipid-sucrester matrix; the SRMS (Sucrosomial® Ratio Matrix System) ratio is proprietary and patent-protected
Formulated to deliver a defined elemental iron content (typically .
**Timing**
Can be taken without regard to meals due to gastric acid resistance; unlike ferrous salts, absorption is not significantly enhanced by fasting or acidic beverages.
**Duration**
Clinical trials report meaningful hematological improvements within 4–12 weeks; full ferritin repletion typically requires 3–6 months of continuous supplementation.
**No Dose Splitting Required**
Once-daily administration is effective; the sucrosome matrix sustains intestinal availability without requiring divided doses to reduce GI load as with ferrous sulfate.
**Form Variants**
Available as hard gelatin capsules, soft-gel capsules, oral sachets (powder for suspension), and chewable tablets depending on regional pharmaceutical registration.
Nutritional Profile
Each standard dose of Sucrosomial® Iron (e.g., Sideral® Forte capsule) delivers 30 mg of elemental iron in the Fe³⁺ form as ferric pyrophosphate, encapsulated within a matrix of approximately 200–300 mg of phospholipids (predominantly lecithin, a source of phosphatidylcholine) and sucrester (sucrose esters of fatty acids). The phospholipid component contributes negligible caloric or macronutrient value at supplemental doses. Bioavailability of the iron fraction is estimated at 3–4× that of ferrous sulfate on a molar basis, meaning a 30 mg elemental iron dose delivers an absorbed iron equivalent approaching that of 90–120 mg of ferrous sulfate without the associated GI burden. No co-factors such as ascorbic acid are required for absorption enhancement, as the uptake mechanism is independent of luminal redox chemistry; however, the formulation contains no added vitamin C, B12, folate, or other erythropoietic co-nutrients unless explicitly combined in a multi-ingredient product.
How It Works
Mechanism of Action
Ferric pyrophosphate within the sucrosome matrix is shielded from gastric acid by the sucrester-phospholipid bilayer shell, which remains structurally intact at simulated gastric pH, preventing premature Fe³⁺ release that would otherwise form insoluble ferric hydroxide precipitates. Upon reaching the small intestine, the intact sucrosome particles are taken up by enterocytes and M cells of Peyer's patches via transcellular endocytosis as well as paracellular diffusion, a mechanism confirmed in ex vivo Ussing chamber studies using rat intestinal segments with the iron-specific chelator bathophenanthroline disulfonate (BPDS) to quantify transepithelial iron flux. This intestinal uptake route is largely independent of the divalent metal transporter-1 (DMT-1) system that requires prior reduction of Fe³⁺ to Fe²⁺ by duodenal cytochrome B (DcytB), thereby circumventing hepcidin-mediated downregulation of DMT-1 that restricts conventional ferrous salt absorption during inflammation. Once inside enterocytes, iron is released from the matrix, incorporated into ferritin stores or transferred to transferrin in the circulation, ultimately restoring systemic iron pools, erythropoiesis, and hemoglobin synthesis.
Clinical Evidence
The most cited clinical trial enrolled 25 Hodgkin's Lymphoma patients with baseline hemoglobin of 10.2 g/dL and administered Sucrosomial® Iron (Sideral® Forte, 30 mg elemental iron/day) for six months, yielding hemoglobin of 12.8 g/dL, serum iron rising from 35 to 95 µg/dL, TIBC from 244 to 264 µg/dL, and ferritin from 90 to 277 ng/mL, all with p<0.05 significance, 100% adherence, and no GI adverse events. In heart failure patients with reduced ejection fraction and concurrent iron deficiency, Sucrosomial® Iron improved functional exercise capacity and health-related quality-of-life metrics, though precise effect sizes from this indication remain to be quantified in larger RCTs. Broader systematic reviews and meta-analyses encompassing over 7,000 participants consistently confirm superior hematological response rates and markedly lower GI side-effect rates (<5%) compared to ferrous sulfate (up to 70% GI adverse events), supporting its use as first-line therapy in refractory or intolerant patients. Confidence in short-term efficacy and tolerability outcomes is high based on the volume and consistency of data; confidence in long-term outcomes, optimal dosing in specific disease states, and direct non-inferiority to IV iron requires further large-scale prospective investigation.
Safety & Interactions
Sucrosomial® Iron is exceptionally well-tolerated at the standard 30 mg/day dose, with published clinical data reporting gastrointestinal adverse events (nausea, constipation, abdominal cramping, dark stools) in fewer than 5% of users, compared with 40–70% for equidose ferrous sulfate; no serious adverse events attributable to the formulation have been reported across more than 7,000 trial participants. Drug interactions are markedly reduced relative to ferrous salts because the sucrosome matrix prevents free iron from interacting with tetracyclines, fluoroquinolones, levothyroxine, or proton pump inhibitors in the gastric environment; standard precautions for concurrent iron supplementation with these agents are nonetheless recommended until dedicated interaction studies are completed. Absolute contraindications mirror those of all iron supplements: hemochromatosis, hemosiderosis, hemolytic anemias not associated with iron deficiency, and known hypersensitivity to any matrix component (lecithin, sucrose esters). Sucrosomial® Iron has been used in pregnancy and pediatric populations in clinical studies without reported safety signals, though formal pharmacokinetic studies in pregnancy are limited and use should follow physician guidance; the theoretical maximum safe upper intake level for elemental iron in adults (45 mg/day from supplements per IOM/FNI) is not exceeded at the standard 30 mg dose.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sucrosomial® Ironferric pyrophosphate sucrosomialSideral® Fortesucrosome ironIron SRMS
Frequently Asked Questions
How does iron sucrosomial compare to ferrous sulfate in absorption?
Iron sucrosomial provides 3–4× greater bioavailability than ferrous sulfate because its sucrosome matrix (phospholipids + sucrester) protects ferric pyrophosphate from gastric acid dissolution and delivers it intact to the small intestine, where it is absorbed via transcellular and paracellular routes independent of DMT-1. This means a 30 mg dose of sucrosomial iron delivers an absorbed iron equivalent approaching that of 90–120 mg of ferrous sulfate, without the gastrointestinal side effects that cause up to 70% of ferrous sulfate users to discontinue therapy.
What are the side effects of iron sucrosomial?
Iron sucrosomial is among the best-tolerated oral iron formulations available; fewer than 5% of users in clinical trials reported gastrointestinal side effects such as nausea, constipation, or abdominal bloating, compared with 40–70% for ferrous sulfate at equivalent iron doses. In one six-month trial in Hodgkin's Lymphoma patients, zero gastrointestinal adverse events were reported with 100% treatment compliance, illustrating the clinical significance of its improved tolerability profile.
What is the recommended dosage of sucrosomial iron?
The most widely studied and clinically validated dose is 30 mg elemental iron once daily, as delivered in Sideral® Forte capsules; this dose has been used in adult IDA, oncology, heart failure, and pediatric studies. Unlike ferrous sulfate, sucrosomial iron can be taken with or without food since its gastric acid-resistant matrix prevents absorption interference from meals, and dose splitting is not necessary to reduce gastrointestinal burden.
Is sucrosomial iron safe during pregnancy?
Sucrosomial iron has been administered to pregnant women in clinical settings and has not produced reported safety signals in published literature, making it a candidate for managing gestational iron deficiency, particularly in women who cannot tolerate ferrous salts. However, formal large-scale pharmacokinetic and teratogenicity studies in pregnancy are limited, and use during pregnancy should be supervised by a healthcare provider who can confirm appropriate dosing and monitor hematological response.
Can sucrosomial iron be used if I cannot tolerate regular iron supplements?
Yes—iron sucrosomial is specifically designed and clinically validated for patients who are intolerant or refractory to conventional ferrous salts (ferrous sulfate, ferrous fumarate, ferrous gluconate); its sucrosome matrix prevents the free iron-mediated oxidative damage to the GI mucosa that causes nausea, cramping, and constipation with standard salts. Across more than 150 studies involving over 7,000 participants, Sucrosomial® Iron consistently produced hematological improvements comparable to intravenous iron in patients who had previously failed or discontinued oral iron therapy.
Does iron sucrosomial interact with medications like antibiotics or thyroid drugs?
Iron sucrosomial has minimal drug interactions due to its encapsulation in the sucrosome matrix, which reduces binding to medications in the gastrointestinal tract compared to conventional iron forms. However, like all iron supplements, it should be taken 2 hours apart from tetracycline antibiotics, fluoroquinolones, and levothyroxine to avoid reduced absorption of these medications. If you take multiple medications, consult your healthcare provider about optimal timing.
Who benefits most from iron sucrosomial supplementation?
Iron sucrosomial is particularly beneficial for individuals with iron deficiency anemia complicated by inflammation, malabsorption disorders (such as celiac disease or Crohn's disease), or those who experience gastrointestinal intolerance with conventional iron supplements. Its 3–4× superior absorption efficiency makes it ideal for patients requiring rapid hemoglobin restoration and those with underlying conditions that impair standard iron uptake. Athletes and menstruating individuals with chronic iron losses may also benefit from its enhanced bioavailability.
What does clinical research show about iron sucrosomial's effectiveness compared to other iron forms?
Clinical studies demonstrate that sucrosomial iron achieves faster restoration of serum ferritin, hemoglobin, and serum iron levels than ferrous sulfate and ferrous gluconate, while maintaining superior gastrointestinal tolerability without the constipation, nausea, or dark stools common with conventional forms. Research indicates efficacy is maintained even in patients with inflammatory conditions or malabsorption, where standard iron supplements often fail. The sucrosome technology's protective matrix allows iron to reach the absorptive sites in the small intestine with minimal premature release.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w iron-sucrosomial-sucrosomial-iron curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
